Tags : Thermo Fisher Scientific

Insights+: COVID-19 Healthcare News Monthly Updates – October 2020

Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it. The COVID-19 virus has been named “SARS-CoV-2” (severe acute respiratory syndrome coronavirus 2) and the disease it causes has been named “Coronavirus Disease 2019” (COVID-19). The outbreak of the respiratory disease was first detected […]Read More

Thermo Fisher Scientific Amends its Agreement to Acquire QIAGEN

Shots: Under the amended agreement, the offer price increased from $44.5 to $49/QIAGEN share in cash, representing a premium of 35% to the closing price of QIAGEN’s ordinary shares on the Frankfurt Prime Standard on Mar 2, 2020, making the latest deal value as $12.5B The amendment also provides for a reduction of the minimum […]Read More

Thermo Fisher Scientific Collaborates with Janssen to Co-Develop CDx for

Shots: The alliance will validate multiple biomarkers to be used in Thermo Fisher’s Oncomine Dx Target Test, which will be used to identify variant-positive patients for enrollment into clinical studies focusing NSCLC and may follow other cancer indications The ability of the Oncomine Dx Target test to rapidly detect variants from small quantities of DNA/ […]Read More

Thermo Fisher Scientific to Acquire QIAGEN for ~$11.5B

Shots: Thermo Fisher to acquire QIAGEN in an all-cash transaction for $43.3/ share, making a total deal value ~$11.5B with a premium of 23% to the closing price of QIAGEN’s common stock on the Frankfurt Prime Standard on Mar 02, 2020. The transaction is expected to be completed in H1’21 The focus of the acquisition […]Read More